|
|
||||||||
Institut für Pharmakologie und Toxikologie, Karl-Franzens-Universität Graz, A-8010 Graz, Austria; und 1 Institut für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität, D-40225 Düsseldorf, Germany
| |
ABSTRACT |
|---|
|
|
|---|
The neuronal and endothelial isoforms of nitric oxide (NO) synthase (nNOS and eNOS, respectively) both catalyze the production of NO but are regulated differently. Stably transfected HEK 293 cell lines containing nNOS, eNOS, and a soluble mutant of eNOS were therefore established to compare their activity in a common cellular environment. NOS activity was determined by measuring L-[3H]citrulline production in homogenates and intact cells, the conversion of oxyhemoglobin to methemoglobin, and the production of cGMP. The results indicate that nNOS is more active than eNOS, both in unstimulated as well as calcium-stimulated cells. Under basal conditions, the soluble mutant of eNOS appeared to be slightly more active than wild-type eNOS in terms of NO and cGMP formation, suggesting that membrane association may be crucial for inhibition of basal NO release but is not required for stimulation by Ca2+-mobilizing agents. The maximal activity of soluble guanylate cyclase was significantly reduced by transfection with wild-type eNOS due to downregulation of mRNA expression. These results demonstrate that nNOS and eNOS behave differently even in an identical cellular environment.
cGMP; soluble guanylate cyclase; stable transfection
| |
INTRODUCTION |
|---|
|
|
|---|
THE TWO CONSTITUTIVELY EXPRESSED ISOFORMS of nitric oxide (NO) synthase (NOS), neuronal (nNOS) and endothelial NOS (eNOS), share large conserved regions of homology and catalyze the production of NO from L-arginine using the same mechanism. However, each isoform also exhibits unique properties that enable it to carry out its specific in vivo function. Both isoforms are activated in the cell by transient increases in intracellular Ca2+, which trigger the binding of Ca2+/calmodulin and subsequent NO production. An important feature of eNOS is its subcellular localization to specialized regions of the plasma membrane termed caveolae (34). This localization is mediated, according to cell type, by various isoforms of caveolin, which dissociate from eNOS upon activation of the enzyme. This interaction is crucial for the regulation of eNOS activity, because receptor-mediated activation of the enzyme is abolished in a soluble mutant of eNOS or by overexpression of caveolin (8). nNOS has also been shown to associate with caveolin-3 in skeletal muscle (36), and both isoforms are inhibited by this interaction (12). Notably, although both NOS isoforms interact with caveolin using highly homologous domains (36), the primary mechanisms of membrane localization differ. Posttranslational acylation is necessary for the membrane association of eNOS (32), whereas a PSD-95/Discs-large/ZO-1 domain (PDZ domain; for details on terminology, see Ref. 27) mediates the subcellular localization of nNOS in muscle cells and neuronal tissue (3, 4). Another inhibitory interaction that is common to both eNOS and nNOS is the binding to the bradykinin B2 receptor (13, 15).
Because both the regulation and functions of the constitutive NOS isoforms are largely determined by their subcellular localization, which in turn is cell type specific, an approach was taken that enabled the characteristics of each isoform to be studied in a common cell line in the absence of these cell type-specific effects. To this aim, stably transfected cell lines were generated containing equivalent amounts of each isoform in the human embryonic kidney cell line HEK 293, which lacks endogenous eNOS (33) but may express low levels of another isoform, as shown indirectly by the small increase in cGMP seen upon stimulation with Ca2+-mobilizing agents (1). In addition, a soluble mutant of eNOS, which lacks the myristoylation site at Gly2, was also studied to enable the importance of membrane association on the functional activity of eNOS to be determined. The results reveal notable differences in the basal and Ca2+-stimulated activities of the three proteins despite the common cellular environment.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials.
HEK 293 cells were obtained from the American Type Culture Collection
(Rockville, MD). 2,2-Diethyl-1-nitroso-oxyhydrazine sodium salt
(DEA/NO) was purchased from Alexis (Lausen, Switzerland). [
-32P]GTP (>3,000 Ci/mmol) was from Humos Diagnostika
(Vienna, Austria). Polyclonal antisera were raised in rabbits against
purified bovine eNOS (20) and purified porcine brain NOS
(17). All other chemicals were purchased from Sigma
(Vienna, Austria). All solutions were prepared in Nanopure water
(Barnstead ultrafiltered type I, resistance > 18 m
/cm).
Plasmid constructs. The pcDNA3 vector (Invitrogen; Groningen, The Netherlands), which contains the neomycin resistance cassette, was used, containing the cDNAs for human nNOS, human eNOS, and a soluble mutant of human eNOS in which the myristoylation site has been removed by a Gly2Ala mutation. Plasmid DNA was prepared for transfection by linearization with the restriction enzyme PvuI, followed by phenol-chloroform extraction and ethanol precipitation.
Transfection and selection of stable lines. HEK 293 cells were transfected at 40% confluency with 5 µg of linearized plasmid DNA using Superfect (Qiagen; Hilden, Germany) or Tfx-50 (Promega; Mannheim, Germany). The cells were trypsinized, counted 48 h after transfection, and replated at 0.5-1 × 106 cells/plate in 100-mm plates in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 1.25 µg/ml amphotericin B, and 1 mg/ml geneticin (antibiotic G418). After 10-12 days, isolated colonies of resistant cells were selected and expanded. In some cases, a limiting dilution was performed to obtain clones arising from single cells. Individual clones were tested for activity (see Determination of NOS activity and [3H]arginine uptake in intact cells), and the following cell lines were maintained in 250 µg/ml G418: cells transfected with wild-type nNOS cDNA (nNOS line); cells transfected with wild-type eNOS cDNA (eNOSwt line); cells transfected with cDNA encoding a soluble mutant of eNOS (eNOSsol line); and cells transfected with vector DNA (Vector line).
Determination of NOS activity and [3H]arginine uptake in intact cells. Confluent monolayers of transfected HEK 293 cells in six-well plates were preincubated in nominal Ca2+-free incubation buffer [composed of (in mM) 50 Tris · HCl, 100 NaCl, 5 KCl, 1 MgCl2, and 0.1 EGTA; pH 7.4] for 15 min in the presence or absence of 100 nM thapsigargin or 300 nM ionomycin. [3H]arginine (~1,000,000 dpm) and CaCl2 (final concentration 0.1-3 mM) were then added, and, after a further 2-min incubation at 37°C, the cells were washed twice with cold wash buffer [composed of (in mM) 50 Tris · HCl, 100 NaCl, 5 KCl, 1 MgCl2, and 5 EDTA; pH 7.4] before being lysed in 10 mM HCl. An aliquot was retained for determination of [3H]arginine uptake, whereas the remainder was adjusted to pH 5.0 using 200 mM sodium acetate (pH 13) and applied to a column (DOWEX 50W X80-40, Sigma) to separate [3H]citrulline from [3H]arginine. Radioactivity was determined using a scintillation counter, and the results are expressed as the percent conversion of incorporated [3H]arginine into [3H]citrulline, as described previously (28).
Preparation of cell homogenates.
Cells were homogenized in 50 mM triethanolamine-HCl buffer (pH 7.4)
containing 12.8 mM
-mercaptoethanol by three cycles of freeze/thawing. The cytosolic protein fraction was obtained by centrifugation at 10,000 g for 5 min. The pellet was washed
twice and then resuspended in homogenization buffer supplemented with 10 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) and 0.5 mM EDTA. After a further three cycles of
freeze/thawing, the homogenate was centrifuged to remove insoluble
material from the solubilized protein fraction. For preparation of
total protein, 10 mM CHAPS and 0.5 mM EDTA were included in the
homogenization buffer. Protein concentration was determined using the
Bradford assay.
Determination of NOS activity in cell homogenates. Protein (50-200 µg) was incubated at 37°C for 10 min with 10 µM [3H]arginine (~50,000 cpm), 10 µg/ml calmodulin, 0.5 mM CaCl2, 10 µM (6R)-5,6,7,8-tetrahydro-L-biopterin, 5 µM FAD, 5 µM flavin-adenine mononucleotide, 200 µM NADPH, and 10 mM CHAPS, as described previously (23). [3H]citrulline was isolated using column chromatography and quantitated in a scintillation counter.
Western blot analysis of NOS proteins. Cytosolic or membrane protein (10 µg) was separated using SDS-PAGE (8% acrylamide), transferred to nitrocellulose, and probed with antibodies specific for either nNOS or eNOS using a previously described method (35).
Measurement of cGMP in intact cells. Cells were preincubated for 15 min in nominal Ca2+-free incubation buffer containing 1 mM isobutyl-methylxanthine and 10 µM indomethacin and then incubated for 4 min with 100 nM thapsigargin, 300 nM ionomycin, or 1 µM DEA/NO in the presence of 3 mM CaCl2. Cells were then lysed in 1 ml of 0.01 N HCl for determination of cGMP content by radioimmunoassay (29). When used, the NOS inhibitor NG-nitro-L-arginine (L-NNA; 300 µM) was added to the culture medium 30 min before preincubation and was present throughout the experiment.
Determination of soluble guanylate cyclase mRNA
expression.
Expression of soluble guanylate cyclase (sGC) mRNA was measured using
competitive RT-PCR (cRT-PCR). A specific cDNA fragment of 698 bp
(positions 66-764) of the
-subunit was amplified using the
following primers: sGC sense primer, 5'-GAA GAC ATC AAA AAA GAG GC-3';
and sGC antisense primer, 5'-GAG AAG ACA GAC AGA AGG C-3',
respectively. An internal deleted sGC cDNA standard of 462 bp was
constructed by linker primer PCR using the following linker primer:
5'-GAA GAC ATC AAA AAA GAG GCA CCT CGC CAC CAT CTA C-3'. The linker
fragment was subsequently cloned into the pCRII TOPO cloning vector
(Invitrogen), and its identity was confirmed by automatic DNA
sequencing. The internal deleted sGC cDNA standard was in vitro
transcribed into cRNA (RNA Transcription Kit, Stratagene). The cRNA was
quantified spectrophotometrically. Increasing amounts of standard RNA
(1-500 pg) were mixed with native RNA (500 ng), reverse
transcribed into cDNA (Superscript TM preamplification system,
GIBCO-BRL), and amplified by PCR. Reaction products were separated by
agarose gel electrophoresis. The optical density of each PCR fragment
was estimated (Bio-Rad Geldoc 1000, Bio-Rad), and the logarithm of the
quotient of normalized standard and sample-specific PCR fragment
density was used to calculate the equivalence point (for details, see
Ref. 18).
Determination of sGC activity in cell homogenates.
Cell homogenates (400 µg total protein) were incubated at 37°C for
20 min in a total volume of 0.2 ml of 50 mM triethanolamine-HCl buffer
(pH 7.4) containing 0.1 mM [
-32P]GTP
(200,000-300,000 counts/min), 5 mM MgCl2, 1 mM cGMP, 1 mM isobutyl-methylxanthine, 5 mM phosphocreatine, 152 U/ml creatine phosphate kinase, 2 mM dithiothreitol, and 1 mM EGTA. Reactions were
started by adding 10-fold concentrated stock solutions of DEA/NO (final
concentration 10 µM) to the assay mixture with subsequent transfer of
the samples from 4 to 37°C. Incubations were stopped by
ZnCO3 precipitation, and [32P]cGMP was
isolated by column chromatography as described previously (31). Results were corrected for enzyme-deficient blanks
and recovery of cGMP.
Measurement of NO.
NO formation was determined using the oxyhemoglobin assay as described
previously (30). Briefly, HEK 293 cells cultured in
six-well plates were incubated for 10 min at 37°C in incubation buffer containing 3 mM CaCl2 and 5 µM oxyhemoglobin in
the absence and presence of 300 nM ionomycin. The increase in the
difference between the absorbances at 402 and 420 nm was monitored, and
NO concentrations were calculated using a molar absorption coefficient of 56 mM
1 · cm
1.
Determination of intracellular Ca2+ levels. HEK 293 cells from one confluent petri dish were harvested, suspended in 5 ml DMEM, and incubated with 2 µM fura-AM at 37°C. After 45 min, cells were washed, resuspended in nominal Ca2+-free incubation buffer, and transferred into a thermostated cuvette. After equilibration (~5 min), cells were preincubated for 15 min in the absence or presence of 300 nM ionomycin or 100 nM thapsigargin, and CaCl2 (final concentration 3 mM) was then added. Fluorescence was measured at excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm, and the intracellular free Ca2+ concentration was calculated using the ratio of fluorescence intensity at 340 to 380 nm.
| |
RESULTS |
|---|
|
|
|---|
Stably transfected cell lines were obtained expressing very
similar high levels of nNOS, eNOS, or a soluble mutant of eNOS. The
specific NOS activities in cell homogenates were <0.1 (Vector), 672 ± 49 (nNOS), 602 ± 18 (eNOSwt), and 640 ± 88 pmol · mg protein
1 · min
1
(means ± SE) (eNOSsol). The majority of eNOS activity was found in the particulate fraction, whereas the mutant eNOS lacking the myristoylation site as well as nNOS were predominantly found in the
cytosol (Fig. 1). This distribution was
also reflected in the Western blot shown in Fig.
2. Densitometric analysis indicated that
34.8 ± 2.6%, 65.9 ± 4.2%, and 77.0 ± 3.4% of
eNOSwt, eNOSsol and nNOS proteins, respectively, were localized in the
soluble fractions of the cells.
|
|
Having established that the homogenates of each stable cell line
exhibited similar NOS activity, experiments were performed to establish
whether differences in activity could be found under identical
conditions in intact cells. To this end, cells were incubated with
[3H]arginine in the presence of increasing concentrations
of extracellular Ca2+ in the presence and absence of
thapsigargin and ionomycin. The former stimulates Ca2+
entry by depleting intracellular Ca2+ stores, whereas the
latter is an ionophore that transports Ca2+ across the
plasma membrane. In the absence of Ca2+-mobilizing agents
(Fig. 3A), both the wild-type
eNOS- and the mutant eNOS-transfected cells showed a very low level of
conversion of [3H]arginine to
[3H]citrulline, which increased only marginally in the
presence of 3 mM extracellular Ca2+. In contrast, the
nNOS-transfected cells exhibited a higher basal NOS activity, which
increased significantly in the presence of 3 mM extracellular
Ca2+. In the presence of ionomycin or thapsigargin (Fig. 3,
B and C), [3H]arginine conversion
increased with increasing extracellar Ca2+ in all three
lines, although the nNOS cell line, again, exhibited the highest
absolute levels of NOS activity. In all cases, the activity of the
soluble mutant of eNOS did not differ significantly from that of the
wild-type isoform, although both these lines had a greater degree of
increase in activity after stimulation compared with the nNOS cells as
a result of their much lower background activity. As shown in Table
1, the two eNOS cell lines showed virtually identical intracellular concentrations of free
Ca2+ upon stimulation by Ca2+-mobilizing
agents. Slightly higher Ca2+ concentrations were measured
in nNOS-transfected cells, but it is rather unlikely that this small
difference explains the higher NOS activity in the nNOS cell line.
Table 2 shows that a similar pattern of
NOS activation was achieved with receptor agonists (carbachol,
bradykinin, and ATP) elevating the concentrations free intracellular
Ca2+ in the presence of two different concentrations of
extracellular Ca2+. Finally, Table
3 demonstrates that the cell transfection
did not affect [3H]arginine uptake.
|
|
|
|
In addition to the conversion of [3H]arginine to
[3H]citrulline as a measure of NOS activity, the
oxyhemoglobin assay was used to assess NO production by the three cell
lines. As seen in the [3H]arginine conversion assay, the
nNOS-transfected cells had significantly higher activity than the
wild-type eNOS cells both in resting and ionomycin-stimulated cells
(Table 4). However, in contrast with the
previous assay, the soluble eNOS mutant-transfected cells produced
1.8-fold more NO under basal conditions than cells transfected with
wild-type eNOS. As a result of the lower basal NO production, wild-type
eNOS showed the greatest percent increase in NO production upon
Ca2+ stimulation.
|
HEK 293 cells express sGC (1), which can be stimulated by
NO to produce cGMP. In an effort to identify any functional differences in NO produced by the three distinct NOS isoforms, cGMP levels were
determined under basal and stimulated conditions. Basal cGMP levels
increased in all the NOS-transfected cell lines upon increasing the
extracellular Ca2+ concentration (Fig.
4A), supporting the
oxyhemoglobin assay results, which showed that low levels of NO are
continuously produced in NOS-transfected cells in the presence of
extracellular Ca2+. This was confirmed using the NOS
inhibitor L-NNA, which reduced the level of basally
produced cGMP to below 2 pmol/mg (data not shown). Basal cGMP levels of
cells in the nNOS line were higher than in the eNOSsol cell line, which
in turn contained significantly more cGMP than cells in the eNOSwt
line. This reflects the relative amounts of NO measured using the
oxyhemoglobin assay. In cells treated with Ca2+-mobilizing
agents, the absolute levels of cGMP were significantly lower in eNOSwt
cells than in either eNOSsol or nNOS cells, which, at the highest
concentration of extracellular Ca2+, had identical cGMP
levels (Fig. 4, B and C). However, the eNOSwt cells showed the greatest degree of increase in activity upon stimulation.
|
The capacity of the transfected cells to produce cGMP in response to NO
was determined by incubation with a maximal concentration of the NO
donor DEA/NO. The maximum cGMP levels obtained in pmol/mg were 70 ± 17 (Vector), 46 ± 3 (eNOSwt), 96 ± 9 (eNOSsol), and 99 ± 7 (nNOS). Thus eNOSwt cells produced significantly less cGMP than the vector controls and the other NOS-transfected cell lines. To
directly compare cGMP production between the three lines, values were
converted to a percentage of the maximum obtained with DEA/NO. This
revealed that, although the eNOSwt cell line produced the least cGMP
under basal conditions (Fig.
5A), all three cells types attained a similar maximum when treated with
Ca2+-mobilizing agents in the presence of 3 mM
extracellular Ca2+ (Fig. 5, B and C).
|
To further investigate the differences in capacity for cGMP production
between the various lines, the specific activity of sGC was determined
in cell homogenates. As shown in Fig. 6,
the eNOS-transfected cell lines exhibited reduced sGC activity compared with vector controls or nNOS-transfected cells. The results obtained with eNOSwt and nNOS cell homogenates agree well with the cGMP levels
in intact cells, but the eNOSsol homogenates apparently exhibited less
sGC activity despite virtually identical capacity of cGMP formation in
the intact cells.
|
As shown in Fig. 7, sGC mRNA expression
was significantly reduced in the eNOSwt cells compared with the other
cell lines, including vector controls. These results agree with the
capacity of the cells to produce cGMP in response to exogenously added NO. However, the data do not explain the apparently reduced specific sGC activity of eNOSsol homogenates.
|
| |
DISCUSSION |
|---|
|
|
|---|
Three stably transfected cell lines, expressing nNOS, eNOS, and a soluble mutant of eNOS, were established. Although all three cell lines contained equivalent amounts of NOS activity, the relative distribution of membrane-associated and cytosolic protein varied. As expected, nNOS was largely found in the cytosol, whereas the majority of wild-type eNOS was membrane associated. The soluble mutant of eNOS was found almost exclusively in the cytoplasm. Thus it appears that myristoylation may be essential for mediating the membrane association of eNOS regardless of the cell type (32), although it cannot be excluded that structural changes of the protein rather than myrostoylation deficiency interferred with membrane association.
The availability of these three NOS isoforms in an identical cell background has enabled for the first time a direct comparison of their function in intact cells. With the use of a variety of methods to assess NOS activity, it could be shown that nNOS is more active in resting cells than either wild-type or soluble eNOS, abeit all three cell lines exhibited virtually identical NOS activity in terms of [3H]citrulline production in cell homogenates. This conclusion is based on the nearly twofold higher conversion of [3H]arginine to [3H]citrulline, the detection of more than twice as much NO using the oxyhemoglobin assay, and significantly higher basal levels of cGMP in nNOS-transfected cells. It should be emphasized that the absence in HEK 293 cells of the membrane-associated proteins to which nNOS normally binds (3, 4) may limit the biologically relevant interpretation of data on nNOS regulation obtained with the transfected HEK cells.
The very low basal activity of wild-type eNOS in an identical intracellular environment is evidence for the almost-complete inhibition of this isoform at resting Ca2+ concentrations. In vivo, NO is tonically produced by the endothelium as a result of exposure of endothelial cells to shear stress, which results in phosphorylation of a serine residue, leading to Ca2+-independent activation of the enzyme (6, 11). In the absence of this mechanism, as in our model, the enzyme remains virtually inactive. The soluble mutant of eNOS exhibited a slightly higher basal activity in terms of both NO and cGMP production, although not L-citrulline production, suggesting that NO is more rapidly inactivated when produced close to membranes, perhaps through the fast reaction with superoxide produced either by endothelial NADPH oxidase (14) or uncoupled eNOS (19).
It has been reported that wild-type eNOS but not the soluble mutant does interact with caveolin-1 in transfected COS-7 cells (8, 24). However, another study (9) from the same group suggests that the mutant does interact with caveolin, albeit with apparently lower affinity compared with the wild-type enzyme. Our results showing that the soluble isoform does not associate with HEK cell membranes in the presence of 10 mM CHAPS seems to agree with these previous findings. However, preliminary results from our laboratory indicate that HEK 293 cells do not express detectable amounts of caveolin-1 and do not contain membrane invaginations visible in electron microscopy (M. Balzer-Geldsetzer, W. Baumgartner, and K. Groschner, unpublished results). Similarly, Rybin et al. (25) recently reported that HEK 293 cells contain neither caveolin-1 nor caveolin-3. Thus the interaction with caveolin does not appear to be required for membrane association of wild-type eNOS in HEK 293 cells.
Upon stimulation with Ca2+-mobilizing agents, nNOS showed the greatest activity in terms of [3H]arginine conversion and NO production as well as cGMP production at submaximal extracellular Ca2+ concentrations. Hence, even in the presence of high intracellular Ca2+, eNOSwt is not as active as nNOS in transfected HEK 293 cells. Although NO has been implicated in the regulation of Ca2+ entry (7), these differences in activity cannot be attributed to isoform-dependent alterations in the intracellular Ca2+ levels, which were found to be identical in the eNOS cell lines and only slightly increased in nNOS-transfected cells.
Despite the slight differences in basal activities, eNOSwt and eNOSsol cells both produced similar amounts of NO or L-[3H]citrulline after stimulation by ionomycin or thapsigargin as well as several receptor agonists, showing that membrane association is not necessary for efficient activation of eNOS by Ca2+. Previously published comparisons of wild-type and soluble eNOS isoforms have described a diminution in activity of the mutant in stably transfected HEK 293 cells (21, 33), transiently transfected COS-7 cells (26), and adenovirus-transfected neurons (16) despite unchanged catalytic properties of the enzyme (32). Feron et al. (8) found no difference in activity between wild-type and soluble eNOS isoforms in Ca2+ ionophore-stimulated cardiac myocytes, but the soluble mutant was unable to respond to receptor-mediated regulation in these cells. Thus it appears that eNOS activity is tightly regulated by the local cellular environment and possibly other factors not yet clarified.
Another novel observation to emerge from comparison of the NOS cell lines is the isoform-dependent alteration in sGC expression. Transfection with wild-type eNOS resulted in a pronounced downregulation of sGC mRNA expression, whereas sGC mRNA levels of eNOSsol and nNOS cells were not significantly different from vector-transfected controls. It has been reported that sGC expression in pulmonary artery smooth muscle cells is downregulated by NO via a decrease in mRNA stability (10). In addition, sGC may become desensitized upon continuous exposure to NO. Such a desensitization of sGC has been demonstrated using isolated cardiomyocytes exposed to S-nitroso-N-acetyl-penicillamine for up to 24 h (5) and by comparing the NO sensitivity of aortas from wild-type and eNOS knockout mice (2). However, because eNOSwt cells exhibited the lowest basal NO production, NO was probably not directly involved in the observed downregulation of sGC expression unless the site of NO production was crucial for its effect. Alternatively, NO produced under basal conditions does indeed reduce sGC mRNA expression, and this effect is counterbalanced in eNOSsol and nNOS cells by other products of NOS catalysis, e.g., superoxide and/or peroxynitrite, which are formed in the course of the partially uncoupled reaction that takes place in conditions of reduced L-arginine or tetrahydrobiopterin availability (22). In any case, after correcting for the differences in sGC content by converting the absolute results to a percentage of the maximum obtained with DEA/NO, the cGMP levels in unstimulated cells correlated well with NO production. Furthermore, the similarity in the amounts of cGMP produced by the three cell lines after stimulation with Ca2+-mobilizing agents in the presence of 3 mM Ca2+ showed that all the NOS isoforms activate sGC to the same extent.
In conclusion, this study has identified several differences in the functional characteristics of nNOS, eNOS, and a soluble mutant of eNOS when overexpressed in HEK 293 cells. The eNOS isoform is the most efficiently regulated, as shown by the lowest basal activity and hence the largest degree of increase upon stimulation, whereas the soluble eNOS mutant is slightly more active under basal conditions, presumably as a result of the loss of inhibitory membrane interaction. However, membrane association does not appear to be necessary for efficient Ca2+ activation of eNOS by receptor agonists and other Ca2+-mobilizing agents.
| |
ACKNOWLEDGEMENTS |
|---|
The authors are indebted to Margit Rehn for excellent technical assistance.
| |
FOOTNOTES |
|---|
This study was supported by Fonds zur Förderung der Wissenschaftlichen Forschung in Austria Grants P14777-GEN (to K. Schmidt), P13759-MED (to P. Andrew), P13211-MED and 13586-MED (to B. Mayer), and F715 (to K. Groschner), by Deutsche Forschungsgemeinschaft Grant KO15557/3-1, and by Forschungskommission of the Heinrich-Heine-Universität Grant FK/Kojda/18-4-2000.
Address for reprint requests and other correspondence: B. Mayer, Institut für Pharmakologie und Toxikologie, Karl-Franzens-Universität Graz, Universitätsplatz 2, A-8010 Graz, Austria (E-mail: mayer{at}kfunigraz.ac.at).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 17 April 2000; accepted in final form 27 July 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Bischof, G,
Serwold TF,
and
Machen TE.
Does nitric oxide regulate capacitative Ca influx in HEK 293 cells?
Cell Calcium
21:
135-142,
1997[Web of Science][Medline].
2.
Brandes, RP,
Kim D,
Schmitz-Winnenthal FH,
Amidi M,
Gödecke LA,
Mülsch A,
and
Busse R.
Increased nitrovasodilator sensitivity in endothelial nitric oxide synthase knockout mice: role of soluble guanylyl cyclase.
Hypertension
35:
231-236,
2000
3.
Brenman, JE,
Chao DS,
Gee SH,
Mcgee AW,
Craven SE,
Santillano DR,
Wu Z,
Huang F,
Xia HH,
Peters MF,
Froehner SC,
and
Bredt DS.
Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha 1-syntrophin mediated by PDZ domains.
Cell
84:
757-767,
1996[Web of Science][Medline].
4.
Brenman, JE,
Chao DS,
Xia HH,
Aldape K,
and
Bredt DS.
Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy.
Cell
82:
743-752,
1995[Web of Science][Medline].
5.
Davis, JP,
Vo XT,
and
Sulakhe PV.
Altered responsiveness of guanylyl cyclase to nitric oxide following treatment of cardiomyocytes with S-nitroso-D,L-acteylpenicillamine and sodium nitroprusside.
Biochem Biophys Res Commun
238:
351-356,
1997[Web of Science][Medline].
6.
Dimmeler, S,
Fleming I,
Fisslthaler B,
Hermann C,
Busse R,
and
Zeiher AM.
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation.
Nature
399:
601-605,
1999[Medline].
7.
Favre, CJ,
Ufret-Vincenty CA,
Stone MR,
Ma HT,
and
Gill DL.
Ca2+ pool emptying stimulates Ca2+ entry activated by S-nitrosylation.
J Biol Chem
273:
30855-30858,
1998
8.
Feron, O,
Dessy C,
Opel DJ,
Arstall MA,
Kelly RA,
and
Michel T.
Modulation of the endothelial nitric-oxide synthase-caveolin interaction in cardiac myocytes: implications for the autonomic regulation of heart rate.
J Biol Chem
273:
30249-30254,
1998
9.
Feron, O,
Michel JB,
Sase K,
and
Michel T.
Dynamic regulation of endothelial nitric oxide synthase: complementary roles of dual acylation and caveolin interactions.
Biochemistry
37:
193-200,
1998[Medline].
10.
Filippov, G,
Bloch DB,
and
Bloch KD.
NO decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells.
J Clin Invest
100:
942-948,
1997[Web of Science][Medline].
11.
Fulton, D,
Gratton JP,
McCabe TJ,
Fontana J,
Fujio Y,
Walsh K,
Franke TF,
Papapetropoulos A,
and
Sessa WC.
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.
Nature
399:
597-601,
1999[Medline].
12.
García-Cardeña, G,
Martásek P,
Masters BSS,
Skidd PM,
Couet J,
Li S,
Lisanti MP,
and
Sessa WC.
Dissecting the interaction between nitric oxide synthase (NOS) and caveolin: functional significance of the NOS caveolin binding domain in vivo.
J Biol Chem
272:
25437-25440,
1997
13.
Golser, R,
Gorren ACF,
Leber A,
Andrew P,
Habisch HJ,
Werner ER,
Schmidt K,
Venema RC,
and
Mayer B.
Interaction of endothelial and neuronal nitric-oxide synthases with the bradykinin B2 receptor: Binding of an inhibitory peptide to the oxygenase domain blocks uncoupled NADPH oxidation.
J Biol Chem
275:
5291-5296,
2000
14.
Görlach, A,
Brandes RP,
Nguyen K,
Amidi M,
Dehghani F,
and
Busse R.
A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall.
Circ Res
87:
26-32,
2000
15.
Ju, H,
Zou R,
Venema VJ,
and
Venema RC.
Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity.
J Biol Chem
272:
18522-18525,
1997
16.
Kantor, DB,
Lanzrein M,
Stary SJ,
Sandoval GM,
Smith WB,
Sullivan BM,
Davidson N,
and
Schuman EM.
A role for endothelial NO synthase in LTP revealed by adenovirus-mediated inhibition and rescue.
Science
274:
1744-1748,
1996
17.
Klatt, P,
Heinzel B,
John M,
Kastner M,
Böhme E,
and
Mayer B.
Ca2+/calmodulin-dependent cytochrome c reductase activity of brain nitric oxide synthase.
J Biol Chem
267:
11374-11378,
1992
18.
Kojda, G,
Cheng YC,
Burchfield J,
and
Harrison DG.
Dysfunctional regulation of endothelial nitric oxide synthase (eNOS) expression in response to exercise in mice lacking one eNOS gene.
Circulation
103:
2839-2844,
2001
19.
Leber, A,
Hemmens B,
Klösch B,
Goessler W,
Raber G,
Mayer B,
and
Schmidt K.
Characterization of recombinant human endothelial nitric-oxide synthase purified from the yeast Pichia pastoris.
J Biol Chem
274:
37658-37664,
1999
20.
List, BM,
Klösch B,
CVölker Gorren ACF,
Sessa WC,
Werner ER,
Kukovetz WR,
Schmidt K,
and
Mayer B.
Characterization of bovine endothelial nitric oxide synthase as a homodimer with down-regulated uncoupled NADPH oxidase activity: tetrahydrobiopterin binding kinetics and role of haem in dimerization.
Biochem J
323:
159-165,
1997.
21.
Liu, J,
García-Cardena G,
and
Sessa W.
Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization.
Biochemistry
35:
13277-13281,
1996[Medline].
22.
Mayer, B,
and
Hemmens B.
Biosynthesis and action of nitric oxide in mammalian cells.
Trends Biochem Sci
22:
477-481,
1997[Web of Science][Medline].
23.
Mayer, B,
Klatt P,
Werner E,
and
Schmidt K.
Molecular mechanisms of inhibition of porcine brain nitric oxide synthase by the antinociceptive drug 7-nitro-indazole.
Neuropharmacology
33:
1253-1259,
1994[Web of Science][Medline].
24.
Robinson, LJ,
and
Michel T.
Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targeting.
Proc Natl Acad Sci USA
92:
11776-11780,
1995
25.
Rybin, VO,
Xu X,
Lisanti MP,
and
Steinberg SF.
Differential targeting of
-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae.
J Biol Chem
275:
41447-41457,
2000
26.
Sakoda, T,
Hirata K,
Kuroda R,
Miki N,
Suematsu M,
Kawashima S,
and
Yokoyama M.
Myristoylation of endothelial cell nitric oxide synthase is important for extracellular release of nitric oxide.
Mol Cell Biochem
152:
143-148,
1995[Web of Science][Medline].
27.
Schepens, J,
Cuppen E,
Wieringa B,
and
Hendriks W.
The neuronal nitric oxide synthase PDZ motif binds to
G(D,E)XV* carboxyterminal sequences.
FEBS Lett
409:
53-56,
1997[Web of Science][Medline].
28.
Schmidt, K,
and
Mayer B.
Assay of tissue activity of nitric oxide synthase.
In: Current Protocols in Toxicology, edited by Maines M,
Costa L,
Reed D,
and Sassa S.. New York: Wiley, 1999, p. 10.2.1-10.2.13.
29.
Schmidt, K,
Mayer B,
and
Kukovetz WR.
Effect of calcium on endothelium-derived relaxing factor formation and cGMP levels in endothelial cells.
Eur J Pharmacol
170:
157-166,
1989[Web of Science][Medline].
30.
Schmidt, K,
Werner ER,
Mayer B,
Wachter H,
and
Kukovetz WR.
Tetrahydrobiopterin-dependent formation of endothelium-derived relaxing factor (nitric oxide) in aortic endothelial cells.
Biochem J
281:
297-300,
1992.
31.
Schultz, G,
and
Böhme E.
Guanylate cyclase. GTP pyrophosphate-lyase (cyclizing), EC.4.6.1.2.
In: Methods of Enzymatic Analysis, edited by Bergmeyer HU,
Bergmeyer J,
and Grassl M.. Weinheim, Germany: Verlag Chemie, 1984, p. 379-389.
32.
Sessa, WC,
Barber CM,
and
Lynch KR.
Mutation of N-myristoylation site converts endothelial cell nitric oxide synthase from a membrane to a cytosolic protein.
Circ Res
72:
921-924,
1993
33.
Sessa, WC,
García-Cardena G,
Liu J,
Keh A,
Pollock JS,
Bradley J,
Thiru S,
Braverman IM,
and
Desai KM.
The Golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide.
J Biol Chem
270:
17641-17644,
1995
34.
Shaul, PW,
Smart EJ,
Robinson LJ,
German Z,
Yuhanna IS,
Ying Y,
Anderson RGW,
and
Michel T.
Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae.
J Biol Chem
271:
6518-6522,
1996
35.
Teubl, M,
Groschner K,
Kohlwein SD,
Mayer B,
and
Schmidt K.
Na+/Ca2+ exchange facilitates Ca2+-dependent activation of endothelial nitric-oxide synthase.
J Biol Chem
274:
29529-29535,
1999
36.
Venema, VJ,
Ju H,
Zou R,
and
Venema RC.
Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain.
J Biol Chem
272:
28187-28190,
1997
This article has been cited by other articles:
![]() |
G. E. Woodard, G. M. Salido, and J. A. Rosado Enhanced exocytotic-like insertion of Orai1 into the plasma membrane upon intracellular Ca2+ store depletion Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1323 - C1331. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tfelt-Hansen, A. Ferreira, S. Yano, D. Kanuparthi, J. R. Romero, E. M. Brown, and N. Chattopadhyay Calcium-sensing receptor activation induces nitric oxide production in H-500 Leydig cancer cells Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1206 - E1213. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Habisch, A. C. F. Gorren, H. Liang, R. C. Venema, J. F. Parkinson, K. Schmidt, and B. Mayer Pharmacological Interference with Dimerization of Human Neuronal Nitric-Oxide Synthase Expressed in Adenovirus-Infected DLD-1 Cells Mol. Pharmacol., March 1, 2003; 63(3): 682 - 689. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |